Completed Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease NCT02023866 Conditions Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +40 more Locations University of California at San Diego (UCSD) — San Diego, California, United States Stanford University — Stanford, California, United States Akron Children's Hospital — Akron, Ohio, United States Baylor College of Medicine — Houston, Texas, United States View more locations Show fewer locations Loading locations... View Trial Details
